Company Focus
Novartis
Latest Novartis News
Biotechnology
Lupus is a rare autoimmune disease characterized by chronic inflammation. It presents in four main forms: systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), drug-induced lupus, and neonatal lupus. 28 May 2025
Related News
Insights
Company Spotlight
A Canada-headquartered provider of antibody development platforms.
Latest News & Features of interest to Novartis
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Biotechnology
India’s Zydus Lifesciences announced that it has entered into a definitive agreement with Agenus to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy. 4 June 2025
Biotechnology
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. 4 June 2025
Pharmaceutical
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward for the drugmakeFood and Drug Administraton,r’s prostate cancer franchise. 4 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC). 3 June 2025
Pharmaceutical
Shares in MaaT Pharma, a French microbiome company in oncology, closed 25% higher Tuesday. 3 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 3 June 2025
Pharmaceutical
Japanese biotech Nxera Pharma has received a $15 million payment from Neurocrine Biosciences after the first patient was dosed in a Phase III study of NBI-1117568, a potential new treatment for schizophrenia. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Latest In Brief for Novartis
Pharmaceutical
Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. 6 June 2025
Latest Ones To Watch News
Shares of USA-based Elevation Oncology leapt more than 20% to $0.38, on the news that it has accepted a takeover bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, an investment firm focused on buying struggling biotechs and shutting them down. 10 June 2025
More in M&A >
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze